Overall Survival in Metastatic NSCLC in HMO From Colombia: A Non-Interventional Study

OBJECTIVES: This study seeks to measure the overall survival in Colombian patients with metastatic non-small cell lung cancer in one Health Management Organization (HMO) between 2018-2022.

METHODS: An observational, descriptive, retrospective study was conducted using the information from one HMO in Colombia. The data from patients with diagnosis of metastatic non-small cells lung cancer (NSCLC) between 2018 to 2022 was collected. International code diseases version 10 was used to identify patients. The index date is defined as the time when the patient is diagnosed with NSCLC. The data associated to demographic and clinical characteristic, treatments, death, and discontinuation were abstracted from electronic healthcare records. Kaplan-meier survival analysis and Cox proportional hazards model were conducted.

RESULTS: Five hundred eighty-nine patients with metastatic NSCLC were included, of which 463 were adenocarcinoma, unknown (227), 72 squamous, and 43 large cells. Ninety-six patients were identified with epidermal growth factor receptor (EGFR), 32 with anaplastic lymphoma kinase (ALK), and 21 with ROS-1, not all patients were evaluated biomarkers (approximately 30%). . Three hundred eighty-two received treatments according to histological and biomarker characteristics, the other group of patients were treated with palliative care. The median of overall survival of patients with adenocarcinoma EGFR, ALK, ROS-1 were 26.4 (IQR 19.8-NA), 45.8 (IQR 30.7-NA), and 45.8 months (IQR 28.8-NA), respectively. In squamous and large cell, it was 8.7 (IQR 5.4 – 13.9) and 11.8 months (95% IQR 6.0-NA). Twenthy four patients with ALK positive who were treated with targeted therapy as first line had best overall survival (34.9 months confidence interval 95% 26.4-NA) than patients with EGFR.

CONCLUSIONS: There overall survival of patients with metastatic NSCLC in Colombia can be different depending on histological and biomarker characteristics of tumor and type of treatment used. ALK+ patients and those with EGFR receiving targeted therapies for first line of treatment had the best OS.